IMM Stock Overview
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.39|
|52 Week High||AU$0.72|
|52 Week Low||AU$0.30|
|1 Month Change||20.00%|
|3 Month Change||20.00%|
|1 Year Change||-41.79%|
|3 Year Change||39.29%|
|5 Year Change||25.81%|
|Change since IPO||-87.00%|
Recent News & Updates
Is Immutep (ASX:IMM) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
|IMM||AU Biotechs||AU Market|
Return vs Industry: IMM underperformed the Australian Biotechs industry which returned -8% over the past year.
Return vs Market: IMM underperformed the Australian Market which returned -0% over the past year.
|IMM Average Weekly Movement||8.9%|
|Biotechs Industry Average Movement||9.9%|
|Market Average Movement||9.3%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: IMM is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: IMM's weekly volatility (9%) has been stable over the past year.
About the Company
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer.
Immutep Fundamentals Summary
|IMM fundamental statistics|
Is IMM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMM income statement (TTM)|
|Cost of Revenue||AU$22.39m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.031|
|Net Profit Margin||-705.34%|
How did IMM perform over the long term?See historical performance and comparison
How is Immutep forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: IMM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IMM's is expected to become profitable in the next 3 years.
Revenue vs Market: IMM's revenue (86.6% per year) is forecast to grow faster than the Australian market (4.8% per year).
High Growth Revenue: IMM's revenue (86.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMM is forecast to be unprofitable in 3 years.
How has Immutep performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMM is currently unprofitable.
Growing Profit Margin: IMM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMM is unprofitable, and losses have increased over the past 5 years at a rate of 23.3% per year.
Accelerating Growth: Unable to compare IMM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).
Return on Equity
High ROE: IMM has a negative Return on Equity (-24.18%), as it is currently unprofitable.
How is Immutep's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IMM's short term assets (A$107.7M) exceed its short term liabilities (A$7.9M).
Long Term Liabilities: IMM's short term assets (A$107.7M) exceed its long term liabilities (A$3.5M).
Debt to Equity History and Analysis
Debt Level: IMM has more cash than its total debt.
Reducing Debt: IMM's debt to equity ratio has reduced from 17.3% to 2.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IMM has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 14.1% each year.
What is Immutep current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marc Voigt (48 yo)
Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD703.09K) is about average for companies of similar size in the Australian market ($USD568.55K).
Compensation vs Earnings: Marc's compensation has increased whilst the company is unprofitable.
Experienced Management: IMM's management team is seasoned and experienced (6.5 years average tenure).
Experienced Board: IMM's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.7%.
Immutep Limited's employee growth, exchange listings and data sources
- Name: Immutep Limited
- Ticker: IMM
- Exchange: ASX
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$328.837m
- Shares outstanding: 854.12m
- Website: https://www.immutep.com
- Immutep Limited
- Australia Square
- Level 33
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.